Aranesp darbepoetin alfa regulatory update

FDA's Cardiovascular and Renal Drugs Advisory Committee will meet on Oct. 18 to discuss the Phase III TREAT trial of Aranesp darbepoetin alfa from Amgen to treat chronic kidney disease (CKD) patients ...